Pritor

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

Telmisartan

Available from:

Bayer AG

ATC code:

C09CA07

INN (International Name):

telmisartan

Therapeutic group:

Sredstva, ki delujejo na sistem renin-angiotenzin

Therapeutic area:

Hipertenzija

Therapeutic indications:

HypertensionTreatment bistvenih hipertenzije pri odraslih. Kardiovaskularni preventionReduction za srčno-žilne obolevnosti pri bolnikih z:manifest atherothrombotic bolezni srca in ožilja (zgodovina bolezni srca in ožilja, kap, ali periferne arterijske bolezni) ali tipa 2 sladkorna bolezen z dokumentiranimi ciljni organ škode.

Product summary:

Revision: 29

Authorization status:

Pooblaščeni

Authorization date:

1998-12-11

Patient Information leaflet

                                23
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
SHRANJUJTE V ORIGINALNI OVOJNINI ZA ZAGOTOVITEV ZAŠČITE PRED VLAGO.
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Bayer AG
51368 Leverkusen
Nemčija
12.
ŠTEVILKA(E) DOVOLJENJA(DOVOLJENJ) ZA PROMET
EU/1/98/089/011
EU/1/98/089/012
EU/1/98/089/020
EU/1/98/089/013
EU/1/98/089/019
EU/1/98/089/014
13.
ŠTEVILKA SERIJE
Lot
14.
NAČIN IZDAJANJA ZDRAVILA
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Pritor 20 mg
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI
PC
SN
NN
24
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI
DVOJNEM TRAKU
PRETISNI OMOT PO 7 TABLET
1.
IME ZDRAVILA
Pritor 20 mg tablete
telmisartan
2.
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Bayer (Logo)
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
4.
ŠTEVILKA SERIJE
Lot
5.
DRUGI PODATKI
PON
TOR
SRE
ČET
PET
SOB
NED
25
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI
DVOJNEM TRAKU
PRETISNI OMOT ZA ENKRATNI ODMEREK ALI VSI TISTI PRETISNI OMOTI, KI NE
VSEBUJEJO PO 7 TABLET
1.
IME ZDRAVILA
Pritor 20 mg tablete
telmisartan
2.
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Bayer (Logo)
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
4.
ŠTEVILKA SERIJE
Lot
5.
DRUGI PODATKI
26
PODATKI NA ZUNANJI OVOJNINI
ŠKATLA
1.
IME ZDRAVILA
Pritor 40 mg tablete
telmisartan
2.
NAVEDBA ENE ALI VEČ UČINKOVIN
1 tableta vsebuje 40 mg telmisartana.
3.
SEZNAM POMOŽNIH SNOVI
Vsebuje sorbitol (E 420).
Za nadaljnje informacije preberite priloženo navodilo.
4.
FARMACEVTSKA OBLIKA IN VSEBINA
14 tablet
28 tablet
30 tablet
56 tablet
90 tablet
98 tablet
280 tablet
28 x 1 tableta
5.
POSTOPEK IN POT(I) UPORABE ZDRAVILA
Peroralna uporaba.
Pred uporabo preberite priloženo navodilo!
6.
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN
POGLEDA OTROK
Zdravilo shran
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Pritor 20 mg tablete
Pritor 40 mg tablete
Pritor 80 mg tablete
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Pritor 20 mg tablete
Ena tableta vsebuje 20 mg telmisartana.
Pritor 40 mg tablete
Ena tableta vsebuje 40 mg telmisartana.
Pritor 80 mg tablete
Ena tableta vsebuje 80 mg telmisartana.
Pomožne snovi z znanim učinkom
Ena 20 mg tableta vsebuje 84 mg sorbitola (E420).
Ena 40 mg tableta vsebuje 169 mg sorbitola (E420).
Ena 80 mg tableta vsebuje 338 mg sorbitola (E420).
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
Tableta
Pritor 20 mg tablete
Bele, 2,5 mm okrogle tablete z vtisnjeno kodno številko 50H na eni in
logom podjetja na drugi strani.
Pritor 40 mg tablete
Bele, 3,8 mm podolgovate tablete z vtisnjeno kodno številko 51H na
eni strani.
Pritor 80 mg tablete
Bele, 4,6 mm podolgovate tablete z vtisnjeno kodno številko 52H na
eni strani.
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Hipertenzija
Zdravljenje esencialne hipertenzije pri odraslih.
Preprečevanje srčnožilnih bolezni
Zmanjševanje pojavnosti srčnožilnih bolezni pri odraslih:

z razvito aterotrombotično srčnožilno boleznijo (anamnezo koronarne
srčne bolezni ali
možganske kapi ali periferne arterijske bolezni) ali

s sladkorno boleznijo tipa 2 s potrjeno okvaro tarčnega organa.
3
4.2
ODMERJANJE IN NAČIN UPORABE
Odmerjanje
_Zdravljenje esencialne hipertenzije_
Običajno učinkovit odmerek je 40 mg enkrat na dan. Pri nekaterih
bolnikih učinkuje že dnevni
odmerek 20 mg. Kadar s priporočenim odmerkom ne dosežemo želenega
znižanja krvnega tlaka,
lahko odmerek telmisartana povečamo do največ 80 mg enkrat na dan.
Telmisartan lahko uporabljamo
tudi v kombinaciji s tiazidnimi diuretiki, kot je npr.
hidroklorotiazid, za katerega se je pokazalo, da
ima v kombinaciji s telmisartanom aditivni učinek na znižanje
krvnega tlaka. Ko presojamo o
povečanju odmerka, moramo upoštevati, da doseže zdravilo največji
antihipertenzivni učinek
veči
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 10-12-2020
Summary of Product characteristics Summary of Product characteristics Bulgarian 10-12-2020
Public Assessment Report Public Assessment Report Bulgarian 05-11-2015
Patient Information leaflet Patient Information leaflet Spanish 10-12-2020
Public Assessment Report Public Assessment Report Spanish 05-11-2015
Patient Information leaflet Patient Information leaflet Czech 10-12-2020
Public Assessment Report Public Assessment Report Czech 05-11-2015
Patient Information leaflet Patient Information leaflet Danish 10-12-2020
Public Assessment Report Public Assessment Report Danish 05-11-2015
Patient Information leaflet Patient Information leaflet German 10-12-2020
Public Assessment Report Public Assessment Report German 05-11-2015
Patient Information leaflet Patient Information leaflet Estonian 10-12-2020
Public Assessment Report Public Assessment Report Estonian 05-11-2015
Patient Information leaflet Patient Information leaflet Greek 10-12-2020
Public Assessment Report Public Assessment Report Greek 05-11-2015
Patient Information leaflet Patient Information leaflet English 10-12-2020
Public Assessment Report Public Assessment Report English 05-11-2015
Patient Information leaflet Patient Information leaflet French 10-12-2020
Public Assessment Report Public Assessment Report French 05-11-2015
Patient Information leaflet Patient Information leaflet Italian 10-12-2020
Public Assessment Report Public Assessment Report Italian 05-11-2015
Patient Information leaflet Patient Information leaflet Latvian 10-12-2020
Public Assessment Report Public Assessment Report Latvian 05-11-2015
Patient Information leaflet Patient Information leaflet Lithuanian 10-12-2020
Summary of Product characteristics Summary of Product characteristics Lithuanian 10-12-2020
Public Assessment Report Public Assessment Report Lithuanian 05-11-2015
Patient Information leaflet Patient Information leaflet Hungarian 10-12-2020
Summary of Product characteristics Summary of Product characteristics Hungarian 10-12-2020
Public Assessment Report Public Assessment Report Hungarian 05-11-2015
Patient Information leaflet Patient Information leaflet Maltese 10-12-2020
Public Assessment Report Public Assessment Report Maltese 05-11-2015
Patient Information leaflet Patient Information leaflet Dutch 10-12-2020
Public Assessment Report Public Assessment Report Dutch 05-11-2015
Patient Information leaflet Patient Information leaflet Polish 10-12-2020
Public Assessment Report Public Assessment Report Polish 05-11-2015
Patient Information leaflet Patient Information leaflet Portuguese 10-12-2020
Summary of Product characteristics Summary of Product characteristics Portuguese 10-12-2020
Public Assessment Report Public Assessment Report Portuguese 05-11-2015
Patient Information leaflet Patient Information leaflet Romanian 10-12-2020
Public Assessment Report Public Assessment Report Romanian 05-11-2015
Patient Information leaflet Patient Information leaflet Slovak 10-12-2020
Public Assessment Report Public Assessment Report Slovak 05-11-2015
Patient Information leaflet Patient Information leaflet Finnish 10-12-2020
Public Assessment Report Public Assessment Report Finnish 05-11-2015
Patient Information leaflet Patient Information leaflet Swedish 10-12-2020
Public Assessment Report Public Assessment Report Swedish 05-11-2015
Patient Information leaflet Patient Information leaflet Norwegian 10-12-2020
Summary of Product characteristics Summary of Product characteristics Norwegian 10-12-2020
Patient Information leaflet Patient Information leaflet Icelandic 10-12-2020
Summary of Product characteristics Summary of Product characteristics Icelandic 10-12-2020
Patient Information leaflet Patient Information leaflet Croatian 10-12-2020
Public Assessment Report Public Assessment Report Croatian 05-11-2015

Search alerts related to this product

View documents history